"Our focus remains on building our complex generic pipeline, operational excellence, regulatory compliance and building a differentiated speciality business," Lupin's managing director Nilesh Gupta said.
Lupin's chief executive officer Vinita Gupta said the company plans to develop speciality drug portfolio in US, Japan and Europe. After missing out on the first wave of biosimilars the company aims to develop copies of biological drugs and will begin product filing in next 3-6 months.
Lupin earns around 40 per cent of its revenue from the US market and sales from the market declined 26 per cent on a year-on-year basis. This was on account of sharp erosion in the price of diabetes drug Glumetza. The company will launch over 30 products in the year and expects to receive approvals for products in the US over next couple of months.
Lupin's chief financial officer Ramesh Swaminathan guided that company will maintain Ebidta margin between 21-23 per cent and expects domestic business to bounce back in remaining nine months of FY18.